American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Emergent BioSolutions Inc.

$8.00 -0.87% NYSE: EBS · 15-min delayed

GAITHERSBURG, Maryland
Public · NYSE: EBS
900 employees
Founded 1998

Visit website Follow

$416.4MMarket cap

$742.9MRevenue · FY2025

$52.6MNet income

900Employees

EBSNYSE

2006IPO

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Founded: 1998
Type: Public · NYSE: EBS
Employees: 900
IPO date: Nov 15, 2006
Headquarters: 300 PROFESSIONAL DR
GAITHERSBURG, Maryland 20879
Phone: 240-631-3200
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: EBS NYSE
SEC CIK: 1367644
LEI: 549300YW6TUOX8BE5103
EIN: 141902018
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Emergent BioSolutions Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $742.9M
Net income: $52.6M
Total assets: $1.3B
Market cap: $416.4M
Gross margin: 56.1%
Operating margin: 13.5%
Net margin: 7.1%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $742.9M
Cost of revenue: $326.2M
Gross profit: $416.7M
Operating expenses: $316.6M
Operating income: $100.1M
Income tax: $30.2M
Net income: $52.6M
EPS (basic): $0.98
EPS (diluted): $0.93

Balance sheet

Total assets: $1.3B
Current assets: $662.5M
Total liabilities: $796.0M
Current liabilities: $132.2M
Shareholders’ equity: $522.6M

Cash flow

Operating cash flow: $170.6M
Investing cash flow: $69.4M
Financing cash flow: -$136.6M
Net cash flow: $103.5M

Statements via Polygon.io (SEC filings)

NYSE: EBS

$8.00 -0.87%

15-minute delayed · data by Polygon.io

Past year

$4.74 $13.90

52-week range

Market cap: $416.4M
P/E ratio: 8.6
EPS (diluted): $0.93
Shares outstanding: 52.0M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 15, 2006

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Profitable — net income of $52.6M in FY2025.
Revenue declined 59% from FY2021 to FY2025.
Gross margin of 56.1%, net margin 7.1%.
Trading 42% below its 52-week high.
Valued at a price-to-earnings (P/E) ratio of 8.6.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.